Ceryx’s Cysoni has received funding to commence the first-in-human clinical study of the cardiac rhythm manage

Medical Devices

To commence the first-in-human clinical study of Ceryx’s Cysoni, a cardiac rhythm management device, and commercialise its cardiology technology, new funding raised by Ceryx Medica, which involves Icehouse Ventures, Business Growth Fund, The Development Bank of Wales, Parkwalk Advisors and a consortium of Angel Investors will be used.

Cysoni is a bionic device that uses real-time respiratory modulation to pace the heart. Instead of the strict metronomic beat provided by standard pacemakers, it mimics the natural relationship between heart rhythm and breathing, prompting the heart to pulse as the user breathes. Cysoni's ability to listen to and respond to the body in this manner represents a significant advancement in the treatment of individuals with critical heart diseases.

“Ceryx’s Cysoni has received funding to commence the first-in-human clinical study of the cardiac rhythm management device.“

CEO of Ceryx, Dr Stuart Plant, stated: "Our studies have found that Cysoni’s way of pacing the heart increased cardiac output by twenty per cent, when compared with monotonic pacing. The benefits of this for cardiology patients are potentially life-changing and life-extending because as well as enabling the heart to work more efficiently, Cysoni also repairs the structure of single heart cells. It’s a huge scientific breakthrough. All the signs point to Cysoni being capable of not only making daily life better for those with heart problems, but also of improving the prognosis for even the most seriously ill cardiology patients. This latest round of funding will enable us to develop our technology for human use and embark on the next phrase of rigorous testing."

Dr Plant further explained: "Cysoni will eventually be an implantable device, but for the purpose of the in-human trials we’ll use an external pacemaker device, loaded with Cysoni technology, to pace the hearts of patients with heart failure who have undergone a coronary artery bypass. Normally these patients receive pacing for a few hours after surgery and pacing is then removed. We will pace post-surgery for the whole time they remain in hospital, so we’ll build a really good picture of what Cysoni can do. If patients respond in the same way as our preclinical models, we should see significant improvements in their cardiac performance, which we’re confident will translate to improved outcomes."

CEO of Icehouse Ventures, who led the investment, Robbie Paul, stated: "We’re delighted to back Stuart and his world-class team. The Ceryx Medical technology is nothing short of cutting-edge and the team have achieved impressive results from their trials to date. We look forward to supporting the company as it embarks on first-in-human trials across the United Kingdom and New Zealand for its breakthrough medical device."

See all the latest jobs in Medical Devices
Return to news